A randomized, multiple dose, dose-escalation, double-blind, placebo-controlled phase I trial investigating the optimal safe dose of ALK ragweed tablet Ambrosia artemisiifolian in adult subjects with seasonal rhinoconjunctivitis caused by ragweed pollen allergy
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2012
At a glance
- Drugs Short ragweed pollen allergen extract (Ragwitek) (Primary)
- Indications Allergic rhinoconjunctivitis; Ragweed pollen hypersensitivity
- Focus Adverse reactions
- 22 Mar 2011 Results presented at the 67th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 06 Jul 2007 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History